Vincent O’Neill's Insider Trades & SAST Disclosures
Vincent O’Neill's most recent trade in Iridium Communications Inc was a trade of 23,764 Common Stock done . Disclosure was reported to the exchange on March 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Vincent O’Neill.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iridium Communications Inc | Vincent O’Neill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 23,764 | 50,749 (0%) | 0% | 0 | Common Stock | |
| Iridium Communications Inc | Vincent O’Neill | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 2,187 | 52,936 (0%) | 0% | 0 | Common Stock | |
| Iridium Communications Inc | Vincent O’Neill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 01 Mar 2025 | 1,592 | 26,985 (0%) | 0% | 31.6 | 50,244 | Common Stock |
| Iridium Communications Inc | Vincent O’Neill | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.56 per share. | 01 Mar 2025 | 986 | 51,950 (0%) | 0% | 31.6 | 31,118 | Common Stock |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Dec 2024 | 521 | 20,122 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Dec 2024 | 521 | 2,606 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Dec 2024 | 165 | 19,957 (0%) | 0% | 0.4 | 58 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 17 Sep 2024 | 21,250 | 25,157 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 17 Sep 2024 | 5,556 | 19,601 (0%) | 0% | 0.6 | 3,056 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Sep 2024 | 521 | 4,045 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Sep 2024 | 521 | 3,127 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Sep 2024 | 138 | 3,907 (0%) | 0% | 0.7 | 95 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 1,875 | 1,875 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Jun 2024 | 521 | 3,648 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Jun 2024 | 521 | 3,679 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Jun 2024 | 155 | 3,524 (0%) | 0% | 1.3 | 199 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 2,250 | 6,750 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 2,250 | 5,573 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 521 | 4,169 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 521 | 3,323 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | See Remarks | 14 Mar 2024 | 165 | 5,408 (0%) | 0% | 2.6 | 432 | Common Stock | |
| BioXcel Therapeutics Inc | J. Vincent O'Neill | Chief Medical Officer | 14 Dec 2023 | 521 | 4,690 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | J. O'Neill Vincent | Chief Medical Officer | 14 Dec 2023 | 521 | 2,802 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 14 Sep 2023 | 521 | 5,211 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 14 Sep 2023 | 521 | 2,281 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 14 Jun 2023 | 521 | 1,760 (0%) | 0% | - | Common Stock | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 14 Jun 2023 | 521 | 5,732 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 6,253 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 2,084 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.69 per share. | 14 Mar 2023 | 845 | 1,239 (0%) | 0% | 19.7 | 16,642 | Common Stock |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 20 Jan 2023 | 29,713 | 29,712 | - | - | Employee Stock Option (right to buy) | ||
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 20 Jan 2023 | 29,713 | 0 (0%) | 0% | 30 | 891,390 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent J. O'Neill | Chief Medical Officer | 20 Jan 2023 | 29,713 | 29,713 (0%) | 0% | 0.4 | 12,182 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 14 Mar 2022 | 8,337 | 8,337 | - | - | Restricted Stock Units | ||
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 25 Mar 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | ||
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 17 Feb 2021 | 15,000 | 15,000 (0%) | 0% | 0.4 | 6,150 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 17 Feb 2021 | 15,000 | 59,425 | - | - | Employee Stock Option (right to buy) | ||
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 17 Feb 2021 | 10,000 | 21,047 | - | - | Employee Stock Option (right to buy) | ||
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 17 Feb 2021 | 10,000 | 25,000 (0%) | 0% | 11 | 110,000 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 17 Feb 2021 | 9,573 | 600 (0%) | 0% | 56.6 | 541,832 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 17 Feb 2021 | 6,872 | 10,173 (0%) | 0% | 55.6 | 381,740 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 17 Feb 2021 | 5,655 | 17,045 (0%) | 0% | 54.5 | 307,915 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 17 Feb 2021 | 2,300 | 22,700 (0%) | 0% | 53.8 | 123,671 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 17 Feb 2021 | 600 | 0 (0%) | 0% | 57.2 | 34,302 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 19 Jan 2021 | 25,000 | 25,000 (0%) | 0% | 0.4 | 10,250 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 19 Jan 2021 | 25,000 | 74,425 | - | - | Employee Stock Option (right to buy) | ||
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 19 Jan 2021 | 12,665 | 5,577 (0%) | 0% | 49.3 | 624,005 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 19 Jan 2021 | 6,758 | 18,242 (0%) | 0% | 48.4 | 327,290 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 19 Jan 2021 | 2,700 | 2,877 (0%) | 0% | 50.4 | 136,026 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 19 Jan 2021 | 1,500 | 1,377 (0%) | 0% | 51.5 | 77,175 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 19 Jan 2021 | 1,377 | 0 (0%) | 0% | 52.5 | 72,224 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 28 Dec 2020 | 25,000 | 99,425 | - | - | Employee Stock Option (right to buy) | ||
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 28 Dec 2020 | 25,000 | 25,000 (0%) | 0% | 0.4 | 10,250 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 28 Dec 2020 | 13,969 | 11,031 (0%) | 0% | 50.8 | 709,206 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 28 Dec 2020 | 5,727 | 5,304 (0%) | 0% | 51.7 | 296,372 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 28 Dec 2020 | 3,951 | 1,353 (0%) | 0% | 52.7 | 208,139 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 28 Dec 2020 | 1,353 | 0 (0%) | 0% | 53.5 | 72,440 | Common Stock | |
| BioXcel Therapeutics Inc | Vincent O'Neill | Chief Medical Officer | 26 May 2020 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges